Showing results (161-170 of 481) with videos related to
Sort By:
Pageof 49
Circulation|April 21, 2025
Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER TrialAndre Zimerman, Ana Laura F Kunzler, Brittany N Weber, et al.Journal of the American College of Cardiology|April 23, 2003
Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18David A Morrow, James A de Lemos, Marc S Sabatine, et al.Journal of the American College of Cardiology|May 9, 2020
Cognition After Lowering LDL-Cholesterol With EvolocumabBaris Gencer, François Mach, Jianping Guo, et al.European Heart Journal|September 19, 2021
Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trialKazuma Oyama, Robert P Giugliano, Minao Tang, et al.Journal of the American College of Cardiology|April 6, 2016
Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54Deepak L Bhatt, Marc P Bonaca, Sameer Bansilal, et al.American Heart Journal|September 11, 2021
Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction - findings from the LATITUDE-TIMI 60 trialMatthew A Cavender, Michelle L O'Donoghue, Antonio Abbate, et al.Journal of the American College of Cardiology|February 2, 2008
Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarctionC Michael Gibson, Yuri B Pride, Jacqueline L Buros, et al.Circulation|May 6, 2009
Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomesJessica L Mega, Sandra L Close, Stephen D Wiviott, et al.Circulation|July 26, 2013
AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trialNihar R Desai, Payal Kohli, Robert P Giugliano, et al.The New England Journal of Medicine|December 14, 2016
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and DiabetesBrian A Ference, Jennifer G Robinson, Robert D Brook, et al.Pageof 49